Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

NCT03038399 is registered in ClinicalTrials.gov with ReveraGen BioPharma, Inc. as lead sponsor.

NCT NCT03038399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03038399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
ReveraGen BioPharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 2, 2017
Completion date
April 30, 2020
Enrollment
46 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy